While the details were in the body of the agreement the summary commentary offered by the Company implied .20 would be the conversion price. I figure you should not always have to ask the right question to get the right answer just as a summary explanation should not omit a critical fact(s). Anyway, raising money is not easy and these are difficult times for the industry overall and particularly difficult for our Company. Yet, I prefer our clinical trials and patents pending to selling out of retail shops for small change.

I think I shall keep my mouth shut for a couple weeks and wait until I get news from Israel and then think about the front line intelligence. Just having someone from our Board touring and meeting with the players will provide some emotional lift. (Yeah, there is an office and medical institution with real scientists involved in the process.)